ATP9B

Across TCGA pan-cancer cohorts, ATP9B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ATP9B data layer compared with 28 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ATP9B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP9B expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

LUAD, LSCC, and CCRCC are the cancer types where ATP9B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.739	0.965	.019	8	view →
LSCC	DFS	Quartile	All	0.906	1.000	.009	3	view →
CCRCC	OS	Tertile	II,III,IV	0.834	0.620	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ATP9B–LUAD (DFS)

Open the LUAD breakdown →